on PHAXIAM THERAPEUTICS (isin : FR001400K4B1)
Results of the Combined General Meeting of June 28, 2024
PHAXIAM Therapeutics, a biopharmaceutical company specializing in treatments against resistant bacterial infections, announced the results of its Combined General Meeting held on June 28, 2024. All resolutions recommended by the Board of Directors were adopted.
The resolutions include the approval of the annual accounts for the 2023 financial year and the confirmation of Valérie Faillat as Director. Shareholders also had to approve the executive remuneration policy and statutory modifications.
PHAXIAM has received authorization to issue shares and grant subscription options. Detailed voting results are available on the Company's website.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PHAXIAM THERAPEUTICS news